Biocon · NSE: BIOCON · BSE: 532523
Q3 FY21 results · Oct–Dec 2020
Biocon reported revenue from operations of ₹1,851.00 crore (up 5.9% from Q3 FY20) and net profit of ₹186.60 crore (down 19.0% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,851.00 | 1,748.10 | +5.9% | 1,744.80 | +6.1% |
| Other income | 27.90 | 35.80 | −22.1% | 15.50 | +80.0% |
| Total income | 1,878.90 | 1,783.90 | +5.3% | 1,760.30 | +6.7% |
| Profit before tax | 236.30 | 318.30 | −25.8% | 222.70 | +6.1% |
| Net profit for the period | 186.60 | 230.30 | −19.0% | 195.40 | −4.5% |
| Attributable to shareholders of the company | 168.60 | 202.80 | −16.9% | 169.30 | −0.4% |
| EPS, basic (₹) | 1.42 | 1.71 | −17.0% | 1.43 | −0.7% |
| Net margin (%) | 10.1 | 13.2 | 11.2 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 456.10 | 501.30 | −9.0% | 560.00 | −18.6% |
| Other income | 33.70 | 51.20 | −34.2% | 38.40 | −12.2% |
| Total income | 489.80 | 552.50 | −11.3% | 598.40 | −18.1% |
| Profit before tax | 45.80 | 157.80 | −71.0% | 99.80 | −54.1% |
| Net profit for the period | 33.00 | 120.70 | −72.7% | 95.00 | −65.3% |
| EPS, basic (₹) | 0.28 | 1.02 | −72.5% | 0.80 | −65.0% |
| Net margin (%) | 7.2 | 24.1 | 17.0 |
Consolidated
- Filed with BSE
- 22 Jan 2021, 17:10 IST
- Board meeting
- 21 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jan 2021, 17:10 IST
- Board meeting
- 21 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE